Kyntra Bio: Kidney Diseases trials

The registry lists 14 Kidney Diseases studies with Kyntra Bio as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 7Phase 3 4Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisCompletedNCT01750190Phase 3Results posted
• Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney DiseaseCompletedNCT01630889Phase 2Results posted
• Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With AnemiaCompletedNCT01244763Phase 2Results posted
• Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisCompletedNCT01147666Phase 2Results posted
• Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring DialysisCompletedNCT00761657Phase 2Results posted
• Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDWithdrawnNCT04621331Phase 3
• Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney DiseaseCompletedNCT04059913Phase 4
• FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on DialysisCompletedNCT02652819Phase 3
• FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney DiseaseCompletedNCT02652806Phase 3
• Study of FG-4592 in Subjects With Chronic Kidney Disease in ChinaCompletedNCT01599507Phase 2
• Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in ChinaCompletedNCT01596855Phase 2
• Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB TherapyTerminatedNCT00913393Phase 2
• Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic NephropathyCompletedNCT00754143Phase 1
• Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes MellitusCompletedNCT00102297Phase 1